Nanobiotix (NASDAQ:NBTX) Shares Up 9.7% – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares traded up 9.7% during mid-day trading on Wednesday . The company traded as high as $31.50 and last traded at $32.11. 35,838 shares were traded during trading, a decline of 15% from the average session volume of 42,152 shares. The stock had previously closed at $29.27.

Analyst Upgrades and Downgrades

NBTX has been the subject of several recent research reports. TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Finally, Guggenheim boosted their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nanobiotix has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Nanobiotix Trading Up 2.3%

The firm has a 50-day simple moving average of $27.05 and a 200-day simple moving average of $22.49.

Institutional Investors Weigh In On Nanobiotix

A number of institutional investors have recently added to or reduced their stakes in NBTX. Millennium Management LLC bought a new position in Nanobiotix in the fourth quarter worth about $390,000. Marshall Wace LLP bought a new stake in shares of Nanobiotix in the 4th quarter valued at about $220,000. Optiver Holding B.V. purchased a new position in shares of Nanobiotix in the 3rd quarter worth approximately $101,000. Finally, Royal Bank of Canada raised its stake in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.